Cancer supportive careAustin, Texas

Nervous system
medicines for cancer
patients and survivors

We are developing neuroplastogens for cancer supportive care, starting with the memory and attention problems that can follow cancer treatment.

TL-01Lead neuroplastogenLead optimizationCancer-related cognitive impairment
Our purpose

Addressing the effects
of cancer and its treatment

Cancer and its treatment can affect memory, attention, energy and everyday activities.

Our team combines medicinal chemistry, neuroscience and clinical development to study potential treatments for these problems. We aim to develop medicines that can be used in routine oncology care.

The science behind our approach
Our lead program

Cancer-related
cognitive impairment

TL-01 · Lead program
Preclinical research · Lead optimization

Research into treatments
for “chemo brain”

TL-01 is our lead neuroplastogen program. We are studying its potential as an oral treatment for the cognitive difficulties that can follow cancer treatment.

Its potential benefits, effects in people and clinical treatment requirements remain to be established.

Explore the lead program
Eight research programsTL-01 is our lead programView the portfolio
Our team

Experience in chemistry,
neuroscience and clinical development

Our founders have experience in medicinal chemistry, CNS drug development and company building. Our scientific advisors contribute expertise in psychiatry, CNS drug development and translational research.

Graham PilgerCo-Founder & CEO
Uroš Laban, PhDCo-Founder & CSO
Tanya Ramey, MD, PhDCo-Founder & CMO
Meet our team & advisors
Research and partnerships

Work with Telesti

Contact our team